高流量加温湿化氧疗与标准低流量鼻导管氧疗治疗中度毛细支气管炎(HFWHO随机对照试验):一项开放标签、4期、随机对照试验
该研究为开放标签、4期随机对照试验,纳入澳大利亚新南威尔士州John Hunter医院急诊科或John Hunter儿童医院医疗单元就诊的24个月以下中度毛细支气管炎患儿202例,1:1随机分配至HFWHO组(最大流量1 L/kg/min,上限20 L/min,空气氧气比1:1,最大FiO2 0.6)或标准治疗组(经婴儿鼻导管低流量冷壁氧气100%,最大2 L/min)。主要终点为随机化至最后一次用氧的时间,标准治疗组中位24小时(95%CI 18-28),HFWHO组中位20小时(95%CI 17-34),HR 0.9(95%CI 0.7-1.2),log rank p=0.61,无显著差异。HFWHO组治疗失败14例(14%),标准治疗组33例(33%),p=0.0016;HFWHO组治疗失败前支持时间更长(HR 0.3,95%CI 0.2-0.6,p<0.0001)。标准治疗组33例治疗失败患儿中20例(61%)以HFWHO补救成功。标准治疗组12例(12%)转入ICU,HFWHO组14例(14%),差异-1%(95%CI -7至16),p=0.41。作者认为早期使用HFWHO不能改变中度毛细支气管炎的潜在疾病进程,但可能作为补救治疗减少需要高成本重症监护的患儿比例。
要点
- 在中度毛细支气管炎患儿中,HFWHO组与标准治疗组至停氧时间无显著差异:标准治疗组中位24小时(95%CI 18-28)vs HFWHO组中位20小时(95%CI 17-34),HR 0.9(95%CI 0.7-1.2),log rank p=0.61。
- HFWHO组治疗失败14例(14%),标准治疗组33例(33%),p=0.0016;HFWHO组治疗失败前支持时间更长(HR 0.3,95%CI 0.2-0.6,p<0.0001)。
- 标准治疗组33例治疗失败患儿中20例(61%)以HFWHO补救成功。
- 标准治疗组12例(12%)转入ICU,HFWHO组14例(14%),差异-1%(95%CI -7至16),p=0.41,无显著差异。
- 作者认为早期使用HFWHO不能改变中度毛细支气管炎的潜在疾病进程,但HFWHO可能作为补救治疗以减少需要高成本重症监护的患儿比例。
适用人群与场景
- 年龄小于24个月的中度毛细支气管炎患儿,就诊于澳大利亚新南威尔士州John Hunter医院急诊科或John Hunter儿童医院医疗单元。
处置流程与药物剂量
- HFWHO组:经高流量加温湿化氧疗,最大流量1 L/kg/min,上限20 L/min,空气氧气比1:1,最大FiO2 0.6。
- 标准治疗组:经婴儿鼻导管低流量冷壁氧气100%,最大流量2 L/min。
研究设计与关键结果
- 研究类型:开放标签、4期、随机对照试验;样本量202例,HFWHO组101例,标准治疗组101例;单中心(John Hunter Hospital急诊科或John Hunter儿童医院医疗单元)。
- 主要终点:随机化至最后一次用氧时间,标准治疗组中位24小时(95%CI 18-28)vs HFWHO组中位20小时(95%CI 17-34),HR 0.9(95%CI 0.7-1.2),log rank p=0.61,无显著差异。
- 治疗失败:HFWHO组14例(14%)vs 标准治疗组33例(33%),p=0.0016;HFWHO组治疗失败前支持时间更长(HR 0.3,95%CI 0.2-0.6,p<0.0001)。
- 标准治疗组33例治疗失败患儿中20例(61%)以HFWHO补救成功。
- 转入ICU:标准治疗组12例(12%)vs HFWHO组14例(14%),差异-1%(95%CI -7至16),p=0.41。
- 不良事件:共4例,HFWHO组氧饱和度下降和冷凝水吸入各1例,标准治疗组氧气管脱落2例;均未导致退出试验;无氧疗相关严重不良事件。
证据类型、等级与局限
- 证据类型:开放标签、4期、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为早期使用HFWHO不能改变中度毛细支气管炎的潜在疾病进程。
- 作者认为HFWHO可能作为补救治疗以减少需要高成本重症监护的患儿比例。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Bronchiolitis is the most common lung infection in infants and treatment focuses on management of respiratory distress and hypoxia. High-flow warm humidified oxygen (HFWHO) is increasingly used, but has not been rigorously studied in randomised trials. We aimed to examine whether HFWHO provided enhanced respiratory support, thereby shortening time to weaning off oxygen.
METHODS: In this open, phase 4, randomised controlled trial, we recruited children aged less than 24 months with moderate bronchiolitis attending the emergency department of the John Hunter Hospital or the medical unit of the John Hunter Children's Hospital in New South Wales, Australia. Patients were randomly allocated (1:1) via opaque sealed envelopes to HFWHO (maximum flow of 1 L/kg per min to a limit of 20 L/min using 1:1 air-oxygen ratio, resulting in a maximum FiO2 of 0·6) or standard therapy (cold wall oxygen 100% via infant nasal cannulae at low flow to a maximum of 2 L/min) using a block size of four and stratifying for gestational age at birth. The primary outcome was time from randomisation to last use of oxygen therapy. All randomised children were included in the primary and secondary safety analyses. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12612000685819.
FINDINGS: From July 16, 2012, to May 1, 2015, we randomly assigned 202 children to either HFWHO (101 children) or standard therapy (101 children). Median time to weaning was 24 h (95% CI 18-28) for standard therapy and 20 h (95% CI 17-34) for HFWHO (hazard ratio [HR] for difference in survival distributions 0·9 [95% CI 0·7-1·2]; log rank p=0·61). Fewer children experienced treatment failure on HFWHO (14 [14%]) compared with standard therapy (33 [33%]; p=0·0016); of these children, those on HFWHO were supported for longer than were those on standard therapy before treatment failure (HR 0·3; 95% CI 0·2-0·6; p<0·0001). 20 (61%) of 33 children who experienced treatment failure on standard therapy were rescued with HFWHO. 12 (12%) of children on standard therapy required transfer to the intensive care unit compared with 14 (14%) of those on HFWHO (difference -1%; 95% CI -7 to 16; p=0·41). Four adverse events occurred (oxygen desaturation and condensation inhalation in the HFWHO group, and two incidences of oxygen tubing disconnection in the standard therapy group); none resulted in withdrawal from the trial. No oxygen-related serious adverse events occurred. Secondary effectiveness outcomes are reported in the Results section.
INTERPRETATION: HFWHO did not significantly reduce time on oxygen compared with standard therapy, suggesting that early use of HFWHO does not modify the underlying disease process in moderately severe bronchiolitis. HFWHO might have a role as a rescue therapy to reduce the proportion of children requiring high-cost intensive care.
FUNDING: Hunter Children's Research Foundation, John Hunter Hospital Charitable Trust, and the University of Newcastle Priority Research Centre GrowUpWell.
参考来源
- Kepreotes E, Whitehead B, Attia J, et al. High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): an open, phase 4, randomised controlled trial. Lancet. 2017. PMID: 28161016. doi:10.1016/S0140-6736(17)30061-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。